Alnylam Price To Sales Ratio vs Interest Coverage Analysis

ALNY Stock

USD 149.13 2.09 1.38%

Alnylam Pharmaceuticals financial indicator trend analysis is way more than just evaluating Alnylam Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alnylam Pharmaceuticals is a good investment. Please check the relationship between Alnylam Pharmaceuticals Price To Sales Ratio and its Interest Coverage accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Price To Sales Ratio vs Interest Coverage

Price To Sales Ratio vs Interest Coverage Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alnylam Pharmaceuticals Price To Sales Ratio account and Interest Coverage. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Alnylam Pharmaceuticals' Price To Sales Ratio and Interest Coverage is -0.4. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Interest Coverage in the same time period over historical financial statements of Alnylam Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Alnylam Pharmaceuticals' Price To Sales Ratio and Interest Coverage is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Alnylam Pharmaceuticals are associated (or correlated) with its Interest Coverage. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Coverage has no effect on the direction of Price To Sales Ratio i.e., Alnylam Pharmaceuticals' Price To Sales Ratio and Interest Coverage go up and down completely randomly.

Correlation Coefficient

-0.4

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Alnylam Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Alnylam Pharmaceuticals sales, a figure that is much harder to manipulate than other Alnylam Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.

Interest Coverage

Most indicators from Alnylam Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alnylam Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.At this time, Alnylam Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 7.1 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.41 in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	704.1M	868.6M	1.5B	1.6B
Total Revenue	844.3M	1.0B	1.8B	1.9B

Gross Profit Total Revenue

Alnylam Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Short Long Term Debt Total	Other Liab	Current Deferred Revenue	Long Term Debt	Other Stockholder Equity
Total Assets		0.93	0.92	-0.1	0.95	0.6	-0.97	0.75	0.64	0.92	-0.53	0.72	0.98	0.78	0.96	0.87	0.32	0.91	0.96	0.99	0.96	0.78	0.7	0.43	0.85	0.98
Other Current Liab	0.93		0.86	-0.44	0.91	0.82	-0.97	0.63	0.51	0.86	-0.7	0.74	0.88	0.59	0.91	0.98	0.36	0.99	0.98	0.92	0.94	0.93	0.67	0.26	0.96	0.9
Total Current Liabilities	0.92	0.86		-0.13	0.96	0.59	-0.89	0.66	0.43	0.94	-0.42	0.58	0.85	0.7	0.91	0.79	0.33	0.86	0.92	0.87	0.92	0.68	0.79	0.7	0.74	0.89
Total Stockholder Equity	-0.1	-0.44	-0.13		-0.17	-0.71	0.26	0.05	0.2	-0.13	0.49	-0.26	0.01	0.29	-0.11	-0.56	-0.23	-0.49	-0.31	-0.08	-0.19	-0.58	-0.2	0.27	-0.56	-0.02
Property Plant And Equipment Net	0.95	0.91	0.96	-0.17		0.64	-0.96	0.77	0.45	0.96	-0.46	0.65	0.88	0.73	0.95	0.85	0.4	0.9	0.96	0.91	0.98	0.73	0.72	0.54	0.82	0.95
Net Debt	0.6	0.82	0.59	-0.71	0.64		-0.71	0.27	0.03	0.59	-0.84	0.67	0.51	0.17	0.67	0.84	0.3	0.81	0.77	0.58	0.7	0.91	0.41	0.05	0.83	0.57
Retained Earnings	-0.97	-0.97	-0.89	0.26	-0.96	-0.71		-0.77	-0.55	-0.9	0.6	-0.76	-0.93	-0.74	-0.95	-0.93	-0.38	-0.96	-0.98	-0.96	-0.98	-0.84	-0.67	-0.33	-0.92	-0.97
Accounts Payable	0.75	0.63	0.66	0.05	0.77	0.27	-0.77		0.4	0.73	-0.07	0.7	0.72	0.84	0.72	0.59	0.35	0.63	0.68	0.72	0.75	0.37	0.56	0.27	0.62	0.79
Cash	0.64	0.51	0.43	0.2	0.45	0.03	-0.55	0.4		0.37	-0.34	0.34	0.75	0.6	0.46	0.47	0.03	0.48	0.47	0.71	0.47	0.44	0.37	0.09	0.48	0.62
Non Current Assets Total	0.92	0.86	0.94	-0.13	0.96	0.59	-0.9	0.73	0.37		-0.38	0.62	0.83	0.72	0.91	0.79	0.35	0.86	0.93	0.85	0.93	0.66	0.62	0.57	0.73	0.9
Non Currrent Assets Other	-0.53	-0.7	-0.42	0.49	-0.46	-0.84	0.6	-0.07	-0.34	-0.38		-0.56	-0.53	-0.15	-0.53	-0.71	-0.14	-0.66	-0.64	-0.57	-0.57	-0.9	-0.23	0.1	-0.71	-0.52
Other Assets	0.72	0.74	0.58	-0.26	0.65	0.67	-0.76	0.7	0.34	0.62	-0.56		0.71	0.55	0.71	0.74	0.18	0.74	0.73	0.73	0.71	0.71	0.48	0.03	0.8	0.73
Cash And Short Term Investments	0.98	0.88	0.85	0.01	0.88	0.51	-0.93	0.72	0.75	0.83	-0.53	0.71		0.8	0.93	0.81	0.24	0.85	0.9	0.99	0.9	0.74	0.68	0.37	0.81	0.97
Common Stock Shares Outstanding	0.78	0.59	0.7	0.29	0.73	0.17	-0.74	0.84	0.6	0.72	-0.15	0.55	0.8		0.72	0.51	0.28	0.57	0.66	0.78	0.72	0.38	0.52	0.46	0.5	0.82
Short Term Investments	0.96	0.91	0.91	-0.11	0.95	0.67	-0.95	0.72	0.46	0.91	-0.53	0.71	0.93	0.72		0.84	0.35	0.89	0.96	0.94	0.96	0.75	0.71	0.45	0.82	0.96
Non Current Liabilities Total	0.87	0.98	0.79	-0.56	0.85	0.84	-0.93	0.59	0.47	0.79	-0.71	0.74	0.81	0.51	0.84		0.37	0.99	0.93	0.86	0.88	0.94	0.62	0.17	0.99	0.83
Other Current Assets	0.32	0.36	0.33	-0.23	0.4	0.3	-0.38	0.35	0.03	0.35	-0.14	0.18	0.24	0.28	0.35	0.37		0.37	0.38	0.3	0.39	0.28	0.32	0.14	0.34	0.32
Total Liab	0.91	0.99	0.86	-0.49	0.9	0.81	-0.96	0.63	0.48	0.86	-0.66	0.74	0.85	0.57	0.89	0.99	0.37		0.97	0.9	0.91	0.92	0.69	0.27	0.97	0.87
Property Plant And Equipment Gross	0.96	0.98	0.92	-0.31	0.96	0.77	-0.98	0.68	0.47	0.93	-0.64	0.73	0.9	0.66	0.96	0.93	0.38	0.97		0.93	0.98	0.86	0.69	0.38	0.9	0.94
Total Current Assets	0.99	0.92	0.87	-0.08	0.91	0.58	-0.96	0.72	0.71	0.85	-0.57	0.73	0.99	0.78	0.94	0.86	0.3	0.9	0.93		0.93	0.79	0.69	0.35	0.86	0.97
Property Plant Equipment	0.96	0.94	0.92	-0.19	0.98	0.7	-0.98	0.75	0.47	0.93	-0.57	0.71	0.9	0.72	0.96	0.88	0.39	0.91	0.98	0.93		0.79	0.67	0.42	0.85	0.97
Short Long Term Debt Total	0.78	0.93	0.68	-0.58	0.73	0.91	-0.84	0.37	0.44	0.66	-0.9	0.71	0.74	0.38	0.75	0.94	0.28	0.92	0.86	0.79	0.79		0.5	0.07	0.93	0.74
Other Liab	0.7	0.67	0.79	-0.2	0.72	0.41	-0.67	0.56	0.37	0.62	-0.23	0.48	0.68	0.52	0.71	0.62	0.32	0.69	0.69	0.69	0.67	0.5		0.54	0.63	0.64
Current Deferred Revenue	0.43	0.26	0.7	0.27	0.54	0.05	-0.33	0.27	0.09	0.57	0.1	0.03	0.37	0.46	0.45	0.17	0.14	0.27	0.38	0.35	0.42	0.07	0.54		0.1	0.41
Long Term Debt	0.85	0.96	0.74	-0.56	0.82	0.83	-0.92	0.62	0.48	0.73	-0.71	0.8	0.81	0.5	0.82	0.99	0.34	0.97	0.9	0.86	0.85	0.93	0.63	0.1		0.81
Other Stockholder Equity	0.98	0.9	0.89	-0.02	0.95	0.57	-0.97	0.79	0.62	0.9	-0.52	0.73	0.97	0.82	0.96	0.83	0.32	0.87	0.94	0.97	0.97	0.74	0.64	0.41	0.81

Click cells to compare fundamentals

Alnylam Pharmaceuticals Account Relationship Matchups

Alnylam Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.4B	3.4B	3.6B	3.5B	3.8B	4.0B
Other Current Liab	206.5M	393.8M	494.1M	585.7M	713.0M	748.7M
Total Current Liabilities	956.4M	1.1B	1.2B	767.9M	967.8M	1.0B
Total Stockholder Equity	1.4B	1.0B	588.2M	(158.2M)	(220.6M)	(209.6M)
Property Plant And Equipment Net	646.4M	706.5M	733.6M	738.6M	725.8M	762.1M
Net Debt	(243.4M)	24.6M	177.6M	453.9M	1.9B	2.0B
Retained Earnings	(3.7B)	(4.6B)	(5.4B)	(6.6B)	(7.0B)	(6.7B)
Accounts Payable	49.9M	52.0M	73.4M	98.1M	55.5M	28.9M
Cash	547.2M	496.6M	820.0M	866.4M	812.7M	853.3M
Non Current Assets Total	661.2M	1.2B	774.5M	854.1M	847.2M	889.5M
Non Currrent Assets Other	18.1M	500M	40.9M	115.5M	(3.5B)	(3.4B)
Other Assets	32.9M	40.7M	101.1M	115.5M	132.8M	139.4M
Cash And Short Term Investments	1.5B	1.9B	2.4B	2.2B	2.4B	2.6B
Common Stock Shares Outstanding	109.3M	115.0M	118.5M	121.7M	124.9M	70.4M
Short Term Investments	989.0M	1.4B	1.6B	1.3B	1.6B	1.7B
Liabilities And Stockholders Equity	2.4B	3.4B	3.6B	3.5B	3.8B	4.0B
Non Current Liabilities Total	603.8M	1.3B	1.9B	2.9B	3.1B	3.2B
Other Current Assets	98.4M	90.7M	111.9M	132.9M	126.4M	68.9M
Total Liab	956.4M	2.4B	3.1B	3.7B	4.1B	4.3B
Property Plant And Equipment Gross	425.2M	706.5M	733.6M	738.6M	948.9M	996.3M
Total Current Assets	1.7B	2.2B	2.9B	2.7B	3.0B	3.1B
Accumulated Other Comprehensive Income	(36.5M)	(43.6M)	(33.3M)	(44.7M)	(23.4M)	(22.2M)
Property Plant Equipment	425.2M	465.0M	502.0M	523.5M	602.0M	632.1M
Short Long Term Debt Total	303.8M	521.2M	997.6M	1.3B	2.7B	2.8B
Other Liab	327.7M	352.3M	1.4B	406.4M	467.3M	490.7M
Current Deferred Revenue	396.2M	352.3M	301.8M	42.1M	102.8M	119.3M
Other Stockholder Equity	5.2B	5.6B	6.1B	6.5B	6.8B	7.2B
Short Term Debt	303.8M	329.9M	321.9M	42.0M	96.5M	67.7M
Net Receivables	43.0M	102.4M	198.6M	238.0M	327.8M	344.2M
Common Stock Total Equity	1.1M	1.2M	1.2M	1.2M	1.4M	770.9K
Common Stock	1.1M	1.2M	1.2M	1.2M	1.3M	801.6K
Net Tangible Assets	1.4B	1.0B	588.2M	(158.2M)	(182.0M)	(172.9M)
Retained Earnings Total Equity	(3.7B)	(4.6B)	(5.4B)	(6.6B)	(5.9B)	(5.6B)
Capital Surpluse	5.2B	5.6B	6.1B	6.5B	7.4B	7.8B
Inventory	56.3M	92.3M	122.7M	129.0M	89.1M	93.6M
Non Current Liabilities Other	603.8M	1.6B	1.7B	1.5B	1.6B	1.7B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether Alnylam Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alnylam Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alnylam Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alnylam Pharmaceuticals Stock:

How To Invest In Alnylam

Details

Is Alnylam Stock a good investment?

Details

What is Alnylam Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Alnylam Stock analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Commodity Directory Find actively traded commodities issued by global exchanges
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Transaction History View history of all your transactions and understand their impact on performance

Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.64)

Revenue Per Share

15.974

Quarterly Revenue Growth

0.548

Return On Assets

(0.03)

Return On Equity

(15.01)

The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alnylam Price To Sales Ratio vs Interest Coverage Analysis

Price To Sales Ratio vs Interest Coverage

Price To Sales Ratio vs Interest Coverage Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Interest Coverage

Alnylam Pharmaceuticals fundamental ratios Correlations

Alnylam Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alnylam Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Alnylam Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.99	Other Current Liab
Total Current Assets	+ 0.99	Cash And Short Term Investments
Total Liab	+ 0.99	Non Current Liabilities Total
Long Term Debt	+ 0.99	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.98	Total Assets

Property Plant Equipment	- 0.98	Retained Earnings
Property Plant And Equipment Gross	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Other Current Liab
Retained Earnings	- 0.97	Total Assets
Total Current Assets	- 0.96	Retained Earnings